A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...

Spravato, a ketamine nasal spray, is being subsidized for treatment-resistant depression. Learn about its benefits, usage, and eligibility criteria.

A nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment cheaper for thousands of Australians. It is the first new depression medication ...

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making it much cheaper for the e. Tuesday, 02 January 2024 12:17 GMT.

A McGill-led study could change the way this new treatment is administered in hospitals and clinics. A first-of-its-kind ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...

A nasal spray derived from ketamine is being used to address treatment-resistant depression. The treatment will be more accessible for up to 30,000 Australians ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

A ketamine nasal spray will be subsidised for treatment-resistant depression. Here’s what you need to know about Spravato Nial Wheate, Macquarie University and Shoohb Alassadi, University of Sydney ...